Evidence in favour
- 21 distinct acquisition events survive duplicate and security-type controls.
- Participation spans 13 named insiders rather than one filing source.
- The latest qualifying evidence is fresh, dated 10 Sep 2026.
Company insider dossier
Avalo Therapeutics Inc insider intelligence
AVTX filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
61/100
Accumulation bias
95/100 confidence- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Latest evidence
- 10 Sep 2026
Investment committee read
Accumulation bias
Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.
Watch for market confirmationDecision risks
- Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 16.12 USD
- One-week move
- -16.2%
- Four-week move
- -17.7%
- Fair-value gap
- +28.5%
- Trend signal
- Active
- Relative strength
- -11.1
Directional balance
Controlled event mix
36.2%acquisition
- Acquisition events
- 21
- Disposal events
- 37
- Net value
- -$3.7M
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
829 Jun
006 Jul
013 Jul
020 Jul
327 Jul
003 Aug
410 Aug
1217 Aug
324 Aug
031 Aug
307 Sep
014 Sep
Named participants
Insider conviction by person
DOYLE, MITTIEChief Medical Officer6528 events
SULLIVAN, CHRISTOPHER RYANChief Financial Officer6019 events
JAIN, RITADirector500 events
LIND, KEVIN ROBERTDirector500 events
PHILIP, RON MDirector500 events
HEFFERNAN, MICHAEL THOMASDirector500 events
KANTOFF, AARONDirector500 events
KAPLAN, GILLADirector500 events
NEIL, GARRY ARTHURDirector, Chief Executive Officer500 events
TRUEX, SAMANTHADirector500 events
VARKI, PAULChief Legal Officer498 events
CHAN, MITCHELLDirector281 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable AVTX filing ledger
Showing 1 to 30 of 94.
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
DisposalOptions and derivatives
10185 sharesStock Option (Right to Buy)
Not reportedContext evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
DisposalCommon equity
10185 sharesCommon Stock
$179.5KDirectional evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
AcquisitionCommon equity
10185 sharesCommon Stock
$81.9KDirectional evidence
DOYLE, MITTIEChief Medical Officer
DisposalOptions and derivatives
679 sharesStock Option (Right to Buy)
Not reportedContext evidence
DOYLE, MITTIEChief Medical Officer
DisposalCommon equity
679 sharesCommon Stock
$13.6KDirectional evidence
DOYLE, MITTIEChief Medical Officer
AcquisitionCommon equity
679 sharesCommon Stock
$5.5KDirectional evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
DisposalOptions and derivatives
31031 sharesStock Option (Right to Buy)
Not reportedContext evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
DisposalCommon equity
31031 sharesCommon Stock
$622.3KDirectional evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
AcquisitionCommon equity
31031 sharesCommon Stock
$306.6KDirectional evidence
DOYLE, MITTIEChief Medical Officer
DisposalOptions and derivatives
1000 sharesStock Option (Right to Buy)
Not reportedContext evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
DisposalOptions and derivatives
2876 sharesStock Option (Right to Buy)
Not reportedContext evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
DisposalOptions and derivatives
37945 sharesStock Option (Right to Buy)
Not reportedContext evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
DisposalCommon equity
37945 sharesCommon Stock
$753.3KDirectional evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
AcquisitionCommon equity
37945 sharesCommon Stock
$374.9KDirectional evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
DisposalCommon equity
3749 sharesCommon Stock
$74.8KDirectional evidence
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
AcquisitionCommon equity
2876 sharesCommon Stock
$28.4KDirectional evidence
DOYLE, MITTIEChief Medical Officer
DisposalCommon equity
1000 sharesCommon Stock
$20.0KDirectional evidence
DOYLE, MITTIEChief Medical Officer
AcquisitionCommon equity
1000 sharesCommon Stock
$12.7KDirectional evidence
RILEY, JENNIFERChief Strategy Officer
DisposalCommon equity
2655 sharesCommon Stock
$52.0KDirectional evidence
DOYLE, MITTIEChief Medical Officer
DisposalOptions and derivatives
679 sharesStock Option (Right to Buy)
Not reportedContext evidence
DOYLE, MITTIEChief Medical Officer
DisposalCommon equity
679 sharesCommon Stock
$13.6KDirectional evidence
DOYLE, MITTIEChief Medical Officer
AcquisitionCommon equity
679 sharesCommon Stock
$5.5KDirectional evidence
DOYLE, MITTIEChief Medical Officer
DisposalOptions and derivatives
1000 sharesStock Option (Right to Buy)
Not reportedContext evidence
DOYLE, MITTIEChief Medical Officer
DisposalCommon equity
1000 sharesCommon Stock
$20.0KDirectional evidence
DOYLE, MITTIEChief Medical Officer
AcquisitionCommon equity
1000 sharesCommon Stock
$12.7KDirectional evidence
DOYLE, MITTIEChief Medical Officer
DisposalOptions and derivatives
2875 sharesStock Option (Right to Buy)
Not reportedContext evidence
DOYLE, MITTIEChief Medical Officer
DisposalOptions and derivatives
1779 sharesStock Option (Right to Buy)
Not reportedContext evidence
DOYLE, MITTIEChief Medical Officer
DisposalCommon equity
4654 sharesCommon Stock
$93.1KDirectional evidence
DOYLE, MITTIEChief Medical Officer
AcquisitionCommon equity
2875 sharesCommon Stock
$36.4KDirectional evidence
LIND, KEVIN ROBERTDirector
AcquisitionOptions and derivatives
1105 sharesStock Option (Right to Buy)
$16.6KContext evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.